System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Vincent Hautefeuille is an expert in Oncology at Centre Hospitalier Universitaire Amiens-Picardie (France). As of September 2026, ScienceLeadR ranks Vincent Hautefeuille in the top 1% of experts worldwide for Carcinoma. Vincent Hautefeuille has authored 161 publications, the most recent in 2026, and is an investigator in 32 clinical trials, 18 of them ongoing. SLR score: 764 (community average: 125). How the SLR is computed.

LeadR Profile

Vincent Hautefeuille Centre Hospitalier Universitaire Amiens-Picardie France
764 ScienceLeadR Reputation 764

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gastroenterology - Hepatology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2017 - 2026
Source: PubMed

Centre Hospitalier Universitaire Amiens-Picardie

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 161

Citations

Citations: 2 138 1st author: 3 Last author: 11 Unique author: 1

Main journals

Ann Oncol 29
Dig Liver Dis 15
Eur J Cancer 14
J Clin Oncol 14
Clin Res Hepatol Gastroenterol 6

Best Journals

Ann Oncol 21
J Clin Oncol 11
Lancet Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Incidence and Neoplastic Risk Associated with Colonic Stricture in Paediatric-Onset Crohn's Disease: A Population-based Study.
PMID 42019917 — constriction, pathologic, incidence, crohn disease, colon, inflammatory bowel diseases, diagnosis, gastrointestinal diseases		Clin Res Hepatol Gastroenterol20260
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEO.
PMID 41980356 — retrospective studies, neoplasms, adenocarcinoma, therapeutics		Eur J Cancer20260
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP.
PMID 41980235 — dna mismatch repair, microsatellite repeats, safety, colorectal neoplasms, mmr-deficient		J Clin Oncol Top journal20260
Ability of computed tomography and endoscopic ultrasound to predict pTNM of resected ampullary adenocarcinomas (AC): an analysis of the French Fédération Française de Cancérologie Digestive AC prospective cohort study.
PMID 41713519 — gastroenterology, tomography, adenocarcinoma, cohort studies, predictive value of tests, endoscopy, therapeutics		Gastrointest Endosc20260
Circulating tumor DNA dynamics and clinical outcomes in patients with advanced Colorectal Cancer treated with cetuximab-based induction and maintenance treatment.
PMID 41671078 — circulating tumor dna, cetuximab, induction chemotherapy, neoplasms, disease progression, drug therapy, maintenance, therapeutics, colorectal neoplasms, random allocation, dna, chemotherapy		Clin Cancer Res20260

Clinical Studies 32

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

Phase 2 17
N/A 8
Phase 3 6
Phase 3/Phase 4 1

By status:

Recruiting 19
Completed 8
Unknown 3
Active not recruiting 1
Not yet recruiting 1

By type:

Interventional 29
Observational 3

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 1
multicentricup10 27

Main Topics

Cohort/Consortium Investigators 8

Ongoing Clinical Trials

18 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
ENGIC 06 (PRODIGE 114) FFCD 2401 FRUQUITAS Randomized phase III trial to compare trifluridine tipiracil Fruquintinib versus trifluridine tipiracil alone for metastatic oeso gastric adenocarcinoma
2025-522395-92-00 — trifluridine, adenocarcinoma		Phase 3Recruiting2025
Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first line treatment for patients with PD L1 CPS 5 metastatic gastric cancer A randomized GERCOR phase II study (BIG)
2023-506753-38-00 — neoplasms, adenocarcinoma, nivolumab, therapeutics, gastrointestinal microbiome, stomach neoplasms		Phase 2Recruiting2024
ENGIC 02 PRODIGE 86 FOLFIRINOX SBA Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
2023-505486-92-00 — adenocarcinoma, therapeutics		Phase 2Recruiting2024
SAFE ESO Phase II study evaluating safety and efficacy of Tislelizumab for elderly patients unfit for chemotherapy with advanced esophageal squamous cell carcinoma
2024-518358-17-00 — cells, safety, esophagus, carcinoma, squamous cell, drug therapy, aged, esophageal squamous cell carcinoma, chemotherapy, carcinoma		Phase 2Recruiting2025
Chimioth rapie base de bevacizumab adapt e la pharmacocin tique du bevacizumab en 1 re ligne de traitement du cancer colorectal m tastatique non r s cable tude de phase 3 randomis e multicentrique en double aveugle
2023-507873-16-00 — neoplasms, bevacizumab, therapeutics, colorectal neoplasms		Phase 3/Phase 4Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS